Celldex Therapeutics Inc
NASDAQ:CLDX

Watchlist Manager
Celldex Therapeutics Inc Logo
Celldex Therapeutics Inc
NASDAQ:CLDX
Watchlist
Price: 20.35 USD -0.1% Market Closed
Market Cap: 1.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+211%
Revenue
Forecast
+74%
Operating Income
Forecast
-15%
Net Income
Forecast
-16%

Wall Street
Price Targets

CLDX Price Targets Summary
Celldex Therapeutics Inc

Wall Street analysts forecast CLDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLDX is 63.32 USD with a low forecast of 36.36 USD and a high forecast of 94.5 USD.

CLDX Lowest Forecast
Wall Street Target
36.36 USD
79% Upside
CLDX Average Forecast
Wall Street Target
63.32 USD
211% Upside
CLDX Highest Forecast
Wall Street Target
94.5 USD
364% Upside
Lowest
Price Target
36.36 USD
79% Upside
Average
Price Target
63.32 USD
211% Upside
Highest
Price Target
94.5 USD
364% Upside
Celldex Therapeutics Inc Competitors:
Price Targets
OXB
Oxford BioMedica PLC
68% Upside
300896
Imeik Technology Development Co Ltd
32% Upside
1801
Innovent Biologics Inc
0% Upside
ZNTL
Zentalis Pharmaceuticals Inc
407% Upside
OXB
Oxford BioMedica PLC
68% Upside
300896
Imeik Technology Development Co Ltd
32% Upside
1801
Innovent Biologics Inc
0% Upside
ZNTL
Zentalis Pharmaceuticals Inc
407% Upside
SYRE
Spyre Therapeutics Inc
271% Upside
PHM
Pharma Mar SA
9% Upside
AGIO
Agios Pharmaceuticals Inc
89% Upside
688428
InnoCare Pharma Ltd
16% Downside

Revenue
Forecast

Revenue Estimate
Celldex Therapeutics Inc

For the last 8 years the compound annual growth rate for Celldex Therapeutics Inc's revenue is 0%. The projected CAGR for the next 3 years is 74%.

0%
Past Growth
74%
Estimated Growth
Estimates Accuracy
18%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Celldex Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Celldex Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
What are analyst estimates?

See Also

Summary
CLDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLDX stock valuation using valuation multiples.
Wall Street Estimates
CLDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CLDX's stock price target?
Price Target
63.32 USD

According to Wall Street analysts, the average 1-year price target for CLDX is 63.32 USD with a low forecast of 36.36 USD and a high forecast of 94.5 USD.

What is Celldex Therapeutics Inc's Revenue forecast?
Projected CAGR
74%

For the last 8 years the compound annual growth rate for Celldex Therapeutics Inc's revenue is 0%. The projected CAGR for the next 3 years is 74%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.